Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism?
about
A blocker of N- and T-type voltage-gated calcium channels attenuates ethanol-induced intoxication, place preference, self-administration, and reinstatementRodent models of genetic contributions to motivation to abuse alcoholFurther characterization of the GlyT-1 inhibitor Org25935: anti-alcohol, neurobehavioral, and gene expression effects.Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence.Ethanol consumption: how should we measure it? Achieving consilience between human and animal phenotypesTranslating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues.Genetically selected Marchigian Sardinian alcohol-preferring (msP) rats: an animal model to study the neurobiology of alcoholism.Long-lasting tolerance to alcohol following a history of dependence.Making organisms model human behavior: situated models in North-American alcohol research, since 1950.Critical thoughts on current rodent models for evaluating potential treatments of alcohol addiction and withdrawalPharmacological blockade of corticotropin-releasing hormone receptor 1 (CRH1R) reduces voluntary consumption of high alcohol concentrations in non-dependent Wistar rats.Binge alcohol drinking elicits persistent negative affect in mice.The complexity of alcohol drinking: studies in rodent genetic modelsPharmacogenetic approaches to the treatment of alcohol addiction.Laboratory models of alcoholism: treatment target identification and insight into mechanisms.Medications development to treat alcohol dependence: a vision for the next decade.The alcohol-preferring AA and alcohol-avoiding ANA rats: neurobiology of the regulation of alcohol drinking.Preclinical and clinical pharmacology of alcohol dependence.Preclinical evidence implicating corticotropin-releasing factor signaling in ethanol consumption and neuroadaptation.A key role for corticotropin-releasing factor in alcohol dependenceEffects of naltrexone, duloxetine, and a corticotropin-releasing factor type 1 receptor antagonist on binge-like alcohol drinking in rats.Effects of naltrexone on post-abstinence alcohol drinking in C57BL/6NCRL and DBA/2J micePreclinical Medication Development: New Targets and New Drugs.Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications DevelopmentTargeting brain angiotensin and corticotrophin-releasing hormone systems interaction for the treatment of mood and alcohol use disorders.Acute ethanol challenge inhibits glycogen synthase kinase-3beta in the rat prefrontal cortexThe importance of animals in advancing research on alcohol use disorders.Functional CRH variation increases stress-induced alcohol consumption in primates.Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism.The effects of varenicline on alcohol seeking and self-administration in baboons.Genetic research: who is at risk for alcoholism.Postdependent state in rats as a model for medication development in alcoholism.High Drinking in the Dark (HDID) mice are sensitive to the effects of some clinically relevant drugs to reduce binge-like drinking.The Need for Treatment Responsive Translational Biomarkers in Alcoholism Research.Effects of the benzodiazepine GABAA α1-preferring ligand, 3-propoxy-β-carboline hydrochloride (3-PBC), on alcohol seeking and self-administration in baboons.Effects of naltrexone on alcohol drinking patterns and extinction of alcohol seeking in baboons.Baclofen effects on alcohol seeking, self-administration and extinction of seeking responses in a within-session design in baboons.Multi-modal MRI classifiers identify excessive alcohol consumption and treatment effects in the brain.Efficacy and safety of the glycine transporter-1 inhibitor org 25935 for the prevention of relapse in alcohol-dependent patients: a randomized, double-blind, placebo-controlled trial.The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target?
P2860
Q24613295-58A49916-7CDA-4A9B-9304-CD0EB6ACAE0FQ33359262-CD1393B6-A3A7-41BD-A107-2B3C8F1DEC3CQ33586550-913B1913-A678-4347-A35D-B94D68655892Q33594729-0E80A9F4-B500-4B73-AAFE-D7DD3EF65E75Q33818913-9A6F8E8F-8B5F-4670-A031-FCA3378FDB03Q33940215-7D3E82F9-134B-4913-9DFB-FDFCA66942FFQ34561484-2138FAB3-4B98-406E-8367-D204803C32F3Q34686490-2DCF21BA-2916-4DF6-8457-4038A6704C57Q34762262-CFCC7944-9B18-4EC0-85B7-C1BE56A5D0C2Q35589974-6756311B-2707-43F1-9720-85555C1772BFQ35624173-0AF66D5C-7697-447F-9F39-68CACC1255A3Q35886157-545654B3-BDE4-46A1-AB22-BCA3200C6AD0Q35901025-6C269A82-0A11-4407-9655-1719D6D2D61FQ36126591-976289B6-6E5C-4D37-8C07-68BCEE5E78D5Q36298365-DA0DEA54-E811-461D-9ACB-3189F6E30367Q36357552-09AC13AA-835B-406C-A298-83E684C75AF4Q36589457-80D81E09-6FC3-43CF-BCCE-4366B92C5025Q36709633-F0DB9521-2790-41B3-96EC-5C9D1A995314Q36852840-8A5A66F2-881A-4E00-A2C3-F2919808B049Q36880698-6CB47B75-4434-4AA9-9B87-88A39D0D9A89Q36982413-308B4371-B7F7-4274-B7AD-E70B9927CDA0Q37019174-2ECA26B5-38CF-40DC-BE21-9900402FE30FQ37059156-97165B7F-0F01-4404-A301-3E8B0709614AQ37059221-26EA7E7D-00D9-4419-A213-05DB815DF87EQ37151967-6EE8146E-F75D-4AFD-B572-D8554D706145Q37231849-239E4570-C40A-4A31-8E3A-A468D797C83CQ37313771-2EF51ACB-D9B6-4797-80DB-71838E392FB1Q37321242-8836B230-A44E-4253-8B85-EAC3DC43F2CBQ37386550-9DF83AD5-F340-4E2D-A9C5-FBE93E62D7C4Q37404736-33676136-B565-4968-A6E7-7CA24AF7C239Q37460560-B628A811-E649-41DC-9967-164C29C5349CQ38268791-6C2BCDF9-6821-4E67-A20E-522A7D06197CQ38639263-CBC3055D-3C69-42C8-82D1-CEFBD58464ABQ38848288-E6CAE9C9-8ED2-4E62-A878-85784BDABBDBQ39784438-CAC27389-A53A-4492-A1B8-2930DA60D96FQ41774164-D37BFD18-B8EA-4E0F-80A7-188F44387F0EQ41844916-2C98A985-490E-407A-A288-69171C9F0261Q45951025-8B5BAB49-6984-4C71-894E-E5BBD1528B8EQ47725075-5BCABD1F-FE89-4132-92A1-D4F28F4C4352Q48305886-5DEB42AC-ACC6-400E-84A0-DDDCFE2D25E9
P2860
Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Can experimental paradigms and ...... ve medications for alcoholism?
@ast
Can experimental paradigms and ...... ve medications for alcoholism?
@en
type
label
Can experimental paradigms and ...... ve medications for alcoholism?
@ast
Can experimental paradigms and ...... ve medications for alcoholism?
@en
prefLabel
Can experimental paradigms and ...... ve medications for alcoholism?
@ast
Can experimental paradigms and ...... ve medications for alcoholism?
@en
P1433
P1476
Can experimental paradigms and ...... ve medications for alcoholism?
@en
P2093
P304
P356
10.1080/13556210500314550
P577
2005-12-01T00:00:00Z